Vilya Expands Series A Financing to $71 Million to Advance Computational Drug Design and Develop a New Class of Medicines
June 04, 2024 09:00 ET
|
Vilya, Inc.
Founder and lead investor ARCH Venture Partners is joined by NVIDIA’s NVentures, Menlo Ventures, and MadronaFunding accelerates advancement of Vilya's proprietary computational drug design and...
Vilya Announces New Publication in Science Validating Foundational Approach to Design of Novel Chemically Diverse Macrocycles
April 25, 2024 14:00 ET
|
Vilya, Inc.
– Company creating de novo designed macrocycles with enhanced efficacy that precisely target disease biology – Vilya’s privileged macrocycles have the potential to be applied across broad...